HCW Biologics Inc.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
HCWB$0.95-6.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| Years EndedDecember 31, | ||
|---|---|---|
| 2023 | 2024 | |
| Revenues: | ||
| Revenues | $2,841,794 | $2,566,792 |
| Cost of revenues | (2,281,434) | (1,607,389) |
| Net revenues | 560,360 | 959,403 |
| Operating expenses: | ||
| Research and development | 7,676,316 | 6,388,994 |
| General and administrative | 6,779,515 | 6,839,596 |
| Legal expenses | 6,571,689 | 15,910,480 |
| Reserve for credit losses and other expenses | 5,250,000 | 1,300,000 |
| Total operating expenses | 26,277,520 | 30,439,070 |
| Loss from operations | (25,717,160) | (29,479,667) |
| Interest expense | (283,042) | (631,137) |
| Other income, net | 1,005,925 | 86,990 |
| Net loss | $(24,994,277) | $(30,023,814) |
| Net loss per share, basic and diluted | $(0.70) | $(0.77) |
| Weighted average shares outstanding, basic and diluted | 35,929,446 | 38,793,018 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.